FDA Works To Ease “Traumatic” Advisory Committee Process – Ganley

Recognizing that planning and conducting advisory committee meetings can be "traumatic" for both government and industry, FDA is taking steps to improve the process, said Charles Ganley, the head of the agency's OTC drugs program